Abstract: A radiation-sensitive resin composition contains: a first polymer having a first structural unit including a partial structure obtained by substituting a hydrogen atom of a carboxy group or of a phenolic hydroxy group with an acid-labile group represented by formula (1); and a compound including: a monovalent radiation-sensitive onium cation moiety including an aromatic ring structure which includes a fluorine atom or a fluorine atom-containing group; and a monovalent organic acid anion moiety. Ar1 represents a group obtained by removing one hydrogen atom from a substituted or unsubstituted aromatic ring structure having 5 to 30 ring atoms; R 1 and R2 each independently represent a substituted or unsubstituted monovalent aliphatic hydrocarbon group having 1 to 10 carbon atoms; and * denotes a site bonding to an ethereal oxygen atom in the carboxy group or an oxygen atom in the phenolic hydroxy group.

Abstract: Uneven distribution of current is suppressed even in a condition that semiconductor elements are mounted in a limited area on a circuit board. A power supply device includes a secondary battery cell, charging/discharging FETs, and a circuit board including a first terminal block and a second terminal block. A first charging/discharging FET and a third charging/discharging FET are disposed at a side of the first terminal block on circuit board. A second charging/discharging FET and a fourth charging/discharging FET are disposed at a side of the second terminal block on circuit board. A first current path connecting the first charging/discharging FET in series to the second charging/discharging FET is longer than a second current path connecting the third charging/discharging FET in series to the fourth charging/discharging FET. The first current path includes a first current impeding region configured to impede current flow.

Abstract: Erroneous fuse-blowout during assembling is avoided, thereby improving workability. A power supply device includes a battery unit and a circuit unit electrically connected to the battery unit for controlling charging and discharging. The battery unit includes a series connection including secondary battery cells connected at least in series to one another, a battery-side ground on a low-voltage side of the series connection, and a battery-side output on a high-voltage side of the series connection. The circuit unit includes an overvoltage-detecting fuse configured to detect an overvoltage and to blow upon detecting the overvoltage.

Abstract: Unintentional damage of a power supply device during assembling of the device is avoided to increase workability of the assembling. The power supply device includes secondary battery cells each including an electrode terminal, a battery holder holding the cells, and a circuit board including a control circuit mounted thereon and electrically connected to the cells to control charging and discharging. A method of manufacturing the device includes connecting, to a board-side ground terminal disposed on the board, a battery-side ground terminal drawn outside from the holder as a ground of a total output of the cells electrically connected in series and/or parallel, mounting the board on a surface of the holder, and connecting, to respective one or more board-side intermediate terminals disposed on the board, one or more battery-side intermediate terminals disposed on the holder being electrically connected to at least one of the cells.

Abstract: The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.

Abstract: The present invention provides the compound, 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound.

Abstract: According to one embodiment, a magnetic disk device includes a plurality of disks including a first area to which data is randomly written in normal recording and to which an LBA is added, and a second area to which data is written in shingled recording to write a plurality of tracks overlaid in a radial direction and to which an LBA is added, a plurality of heads, and a controller which writes data to the first area in the normal recording, writes data to the second area in the shingled recording, and changes the first area in accordance with a first recording capacity of a first recording surface in each of the disks, which corresponds to a first head of the heads, when the first head is inhibited from being used.

Abstract: The present invention provides the compound, 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound.

Abstract: The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.

Abstract: The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.

Abstract: A modified conjugated diene polymer obtained by modifying a conjugated diene polymer that is obtained by polymerizing a conjugated diene compound or polymerizing a conjugated diene compound and an aromatic vinyl compound is produced by a production method comprising a first modification step wherein an unsaturated binding site at least either in the skeleton or at the side chain of the conjugated diene polymer is reacted with a first compound having a group 4 or 13 element of the periodic table.

Abstract: A modified conjugated diene-based polymer is produced that is a modified product of a conjugated diene-based polymer obtained by polymerizing a conjugated diene compound, or polymerizing a conjugated diene compound and an aromatic vinyl compound, in the presence of an alkali metal compound or an alkaline-earth metal compound. The modified conjugated diene-based polymer is produced by a production method that includes a main chain modification step that reacts at least either an unsaturated bond or a functional group that is included in a terminal-modified polymer and is not situated at a terminal of the terminal-modified polymer, with a specific compound that includes a functional group that interacts with silica, the terminal-modified polymer being obtained by introducing a functional group that interacts with silica into at least one terminal of the conjugated diene-based polymer.

Abstract: A modified conjugated diene polymer obtained by modifying a conjugated diene polymer that is obtained by polymerizing a conjugated diene compound or polymerizing a conjugated diene compound and an aromatic vinyl compound is produced by a production method comprising a first modification step wherein an unsaturated binding site at least either in the skeleton or at the side chain of the conjugated diene polymer is reacted with a first compound having a group 4 or 13 element of the periodic table.

Abstract: A modified conjugated diene-based polymer is produced that is a modified product of a conjugated diene-based polymer obtained by polymerizing a conjugated diene compound, or polymerizing a conjugated diene compound and an aromatic vinyl compound, in the presence of an alkali metal compound or an alkaline-earth metal compound. The modified conjugated diene-based polymer is produced by a production method that includes a main chain modification step that reacts at least either an unsaturated bond or a functional group that is included in a terminal-modified polymer and is not situated at a terminal of the terminal-modified polymer, with a specific compound that includes a functional group that interacts with silica, the terminal-modified polymer being obtained by introducing a functional group that interacts with silica into at least one terminal of the conjugated diene-based polymer.

Abstract: Provided are a filler for affinity chromatography which has excellent alkali resistance, and a method for isolating immunoglobulin. The filler for affinity chromatography is a filler in which a protein represented by the following formula (1) is immobilized on a carrier. R—R2??(1) wherein R represents an amino acid sequence consisting of 4 to 300 amino acid residues containing a region consisting of 4 to 20 contiguous histidine residues; and R2 represents an amino acid sequence capable of binding to immunoglobulin, the amino acid sequence consisting of 50 to 500 amino acid residues containing Z domain of Protein A or a fragment thereof, or a variant thereof, provided that the R binds to C-terminus or N-terminus of the R2.

Abstract: A platelet aggregation inducing substance containing as an active ingredient a polypeptide having a peptide fragment represented by formula (1) (component A): -(Pro-X-Gly)n-??(1) wherein X represents Pro or Hyp; and n represents an integer of from 20 to 5,000.

Abstract: An affinity chromatography packing material includes porous mother particles that include a copolymer of a monomer mixture including a crosslinkable vinyl monomer and an epoxy group-containing vinyl monomer, a ligand being bound to the porous mother particles, and the porous mother particles including a ring-opening epoxy group produced by ring-opening of the epoxy group included in the porous mother particles.

Abstract: A platelet aggregation inducing substance containing as an active ingredient a polypeptide having a peptide fragment represented by formula (1) (component A): -(Pro-X-Gly)n-??(1) wherein X represents Pro or Hyp; and n represents an integer of from 20 to 5,000.

Abstract: A platelet aggregation inducing substance containing as an active ingredient a polypeptide having a peptide fragment represented by formula (1) (component A): -(Pro-X-Gly)n-??(1) wherein X represents Pro or Hyp; and n represents an integer of from 20 to 5,000.

Abstract: Provided are a filler for affinity chromatography which has excellent alkali resistance, and a method for isolating immunoglobulin. The filler for affinity chromatography is a filler in which a protein represented by the following formula (1) is immobilized on a carrier. R—R2 ??(1) wherein R represents an amino acid sequence consisting of 4 to 300 amino acid residues containing a region consisting of 4 to 20 contiguous histidine residues; and R2 represents an amino acid sequence capable of binding to immunoglobulin, the amino acid sequence consisting of 50 to 500 amino acid residues containing Z domain of Protein A or a fragment thereof, or a variant thereof, provided that the R binds to C-terminus or N-terminus of the R2.